China Galaxy Securities: Innovation and transformation are accelerating into the performance harvest period, and China Biopharmaceutical (01177.HK) was first awarded a “recommended” rating

Zhitong Finance · Apr 14 20:47

China Galaxy Securities released a research report stating that it covered China Biopharmaceuticals (01177.HK) for the first time and gave it a “recommended” rating. The company's generic drug product collection risks have been cleared, and innovative products have entered the performance harvest period. The company's revenue is expected to be RMB 317.30/369.61 billion RMB 41,159 billion in 2024 to 2026, +21/16/ 11% year on year, and net profit to mother is RMB 25.83/31.29/ 3.626 billion yuan respectively, +11/21/ 16%, and corresponding PE is 19/15/13 times, respectively.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

中国银河证券：创新转型加速步入业绩收获期 首予中国生物制药(01177.HK)“推荐”评级

China Galaxy Securities: Innovation and transformation are accelerating into the performance harvest period, and China Biopharmaceutical (01177.HK) was first awarded a “recommended” rating

Risk Disclaimer

Statement

中国银河证券：创新转型加速步入业绩收获期首予中国生物制药(01177.HK)“推荐”评级